<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04803123</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00105967</org_study_id>
    <nct_id>NCT04803123</nct_id>
  </id_info>
  <brief_title>Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL</brief_title>
  <official_title>Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in Relapsed or Refractory Adult B-cell Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dorothy Sipkins, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide an evaluation of biologic markers of leukemia cell response following&#xD;
      a single dose of copanlisib prior to any salvage induction therapy in a projected cohort of&#xD;
      10 relapsed/refractory B-ALL patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effect of copanlisib exposure on alpha-6 integrin expression levels in leukemic blasts using flow cytometry.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of copanlisib exposure on proliferation of ALL blasts as determined by flow cytometric blast cell Ki-67 index.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of copanlisib exposure on proliferation of ALL blasts as determined by peripheral blood hematologic parameters (CBC and WBC differential including blast percentage).</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Leukemia, Acute Lymphocytic</condition>
  <arm_group>
    <arm_group_label>Copanilisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copanlisib</intervention_name>
    <description>Patients must receive at least one dose of copanlisib prior to standard therapy to be evaluable.</description>
    <arm_group_label>Copanilisib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Relapsed/refractory, Philadelphia chromosome positive or negative, B-cell, adult (≥&#xD;
             age 18) acute lymphoblastic leukemia (including bone marrow, extramedullary, CNS&#xD;
             disease, or all), with or without prior hematopoietic stem cell transplant.&#xD;
&#xD;
             Philadelphia chromosome positive patients prior to enrollment must have documented&#xD;
             treatment failure to all FDA-approved for use in R/R ALL tyrosine kinase inhibitor&#xD;
             (TKI) therapy, or have previously been deemed by their treating physician to not be a&#xD;
             candidate for further TKI therapy.&#xD;
&#xD;
          2. ECOG 0-3.&#xD;
&#xD;
          3. CrCl ≥ 30 mL/minute.&#xD;
&#xD;
          4. Bilirubin ≤ 1.5x upper limit of normal (ULN), AST/ALT ≤ 3x ULN.&#xD;
&#xD;
          5. Any patients with known pulmonary disease (including COPD, asthma, ongoing tobacco&#xD;
             use, pulmonary hypertension, pulmonary sarcoidosis, or other relevant pulmonary&#xD;
             disease which severely limits their pulmonary function), require an assessment of lung&#xD;
             capacity with pulmonary function testing prior to acceptance to the study, with a&#xD;
             threshold acceptance of DLCO &gt; 40% corrected.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of or concurrent condition of interstitial lung disease or autoimmune&#xD;
             pneumonitis.&#xD;
&#xD;
          2. Active pneumonia requiring treatment, including Pneumocystis jirovecci pneumonia&#xD;
             (PJP).&#xD;
&#xD;
          3. History of type 1 diabetes mellitus.&#xD;
&#xD;
          4. Type 2 diabetes mellitus with HgbA1C ≥10% while on treatment for diabetes.&#xD;
&#xD;
          5. Uncontrolled hypertension despite optimal medical management (per investigator's&#xD;
             assessment).&#xD;
&#xD;
          6. Untreated human immunodeficiency virus (HIV).&#xD;
&#xD;
          7. Active replication of hepatitis B or active hepatitis C. Those with prior disease who&#xD;
             are PCR negative at enrollment and meet liver function eligibility criterion are&#xD;
             eligible.&#xD;
&#xD;
          8. Cytomegalovirus (CMV) infection with positive PCR at baseline. CMV PCR test is&#xD;
             considered positive if the result can be interpreted as a CMV viremia according to&#xD;
             institutional standard.&#xD;
&#xD;
          9. History of hematopoietic stem cell transplant with active GVHD requiring &gt; 10 mg of&#xD;
             prednisone daily or equivalent.&#xD;
&#xD;
         10. History of calcineurin inhibitor use in the last 28 days prior to enrollment.&#xD;
&#xD;
         11. Patients requiring immediate cytoreductive therapy. Exceptions for: patients whose&#xD;
             peripheral blast counts are being controlled by single agent or combination therapy&#xD;
             with steroids and/or hydroxyurea.&#xD;
&#xD;
         12. Pregnancy.&#xD;
&#xD;
         13. Active concurrent malignancy requiring ongoing treatment. Exceptions for: resected&#xD;
             breast cancer being treated with hormonal therapy only, prostate cancer treated with&#xD;
             hormonal therapy not progressing within the past year, if subject has received&#xD;
             definitive local therapy (i.e., surgical excision, external beam radiation, or other&#xD;
             local therapy with curative intent), non-melanoma skin cancers, or carcinoma in situ.&#xD;
&#xD;
         14. Active COVID-19 infection.&#xD;
&#xD;
         15. Progressive and/or uncontrolled infections despite active treatment.&#xD;
&#xD;
         16. Patients with residual toxicities related to prior treatment (including chemotherapy,&#xD;
             immunotherapy, clinical trial, surgery, radiotherapy, or hematopoietic stem cell&#xD;
             transplant) persistently &gt; Grade 1 despite adequate treatment. Exceptions for:&#xD;
             patients with residual toxicity related to prior treatment of ≤Grade 2 which is stable&#xD;
             prior to enrollment and for which the natural history would not be expected to change&#xD;
             over time; toxicity which cannot be reasonably excluded to be due to disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorothy Sipkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorothy Sipkins, MD</last_name>
    <phone>919-613-5010</phone>
    <email>dorothy.sipkins@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Prioty Islam</last_name>
    <phone>919 684 8111</phone>
    <email>prioty.islam@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothy Sipkins, MD</last_name>
      <phone>919-613-5010</phone>
      <email>dorothy.sipkins@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Dorothy Sipkins, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

